What Can You Expert at the 4th Circular & Self-Amplifying RNA Therapeutics Summit!
Curated in collaboration with key stakeholders, the 4th Circular & Self-Amplifying RNA Therapeutics Summit returns as the only industry dedicated event showcasing the latest approaches and applications of these next generation RNAs for more potent and durable treatment of a wide array of diseases.
Industry experts will navigate through presentations and interactive discussions to:
OPTIMIZE
self-amplifying mRNA sequence design as well as circularization of mRNA to achieve improved stability, durability and functionality for more potent and efficacious therapeutics with Virogin Biotech & CSL Seqirus
ACHIEVE
efficient RNA encapsulation and specificity with new and innovative formulations for safe and targeted delivery of circular and self-amplifying RNA with HDT Bio & Stealth-Mode Biotech Company
IMPROVE
purity and scalability through navigating manufacturing and analytical challenges for attaining large-scale production of high-quality circular and self-amplifying RNA therapies with Merck & Co & Immunomic Therapeutics
UNDERSTAND
the full potential of next generation RNAs and their benefits over linear mRNA for treating a wide array of diseases with Sail Biomedicines, RiboX Therapeutics & Replicate Bioscience
BOOST
investment of circular and self-amplifying RNAs by hearing insights into the current trends and key priority applications with MPM Capital & Orbital Therapeutics
Key Sessions Showcasing Brand New Data
Engineering Sa-mRNA Structure to Improve Vaccine Product Stability & Functionality
Fei Liu, Associate Director, Molecular Biology, CSL Seqirus
Advancing Analytical Methods Enabling Circular RNA Pharmaceutical Preparedness
Nichole Lareau, Associate Principal Scientist, Merck & Co
In Vivo Reversible Programming of T cells with SAIL’s Targeted NP-eRNA Platform for Treatment of Autoimmune Diseases & Beyond
Michael Mingueneau, Head, Immunology, Sail Biomedicines
Circular RNA: Transforming a Promising Technology into Cutting-Edge Therapeutics
Edo Kon, Director, Business Development, RiboX Therapeutics
Myeloid Cell Targeting Cancer Immunotherapy via Localized Gene Delivery with Alphavirus Replicon Particles (VRP) Expressing IL-12
Momoko Ishikawa, Senior Scientist, VLP Therapeutics
New Companies For 2025
What Your Peers Have to Say:
“Engage with thought leaders in our field to foster collaboration and drive advancements"
Edo Kon, Director, Business Development
“Attending the Circular & Self-Amplifying RNA Therapeutics Summit would provide valuable insights into the latest innovations in RNA-based therapies, which is essential for staying at the forefront of the field. It offers an excellent opportunity to network with industry leaders, exchange ideas, and explore potential collaborations”
Dinesh Chandra, Lead Consultant Scientist
